Priority Review for denosumab in SREs

FDA accepted for filing and granted Priority Review to a BLA from Amgen Inc. (NASDAQ:AMGN) for denosumab to treat bone metastases to reduce skeletal related events (SREs) in cancer patients. The PDUFA...